New obesity drug ABBV-295 enters early human testing

NCT ID NCT07291232

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage study tests the safety and tolerability of a new injectable drug called ABBV-295 in 48 adults with obesity. Participants will receive either the drug or a placebo over several weeks. Researchers will monitor side effects, changes in body weight, and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-295 (injectable drug)
What this could lead to: If successful, this could lead to a new treatment option for obesity that helps with weight loss.
What could go wrong: This is an early Phase 1b study with only 48 people, focused on safety and dosing. It is too soon to know if ABBV-295 will be effective or have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Acpru /Id# 278624
RECRUITING

Grayslake, Illinois, 60030, United States
CenExel Act- Anaheim Clinical Trials /ID# 283200
RECRUITING

Anaheim, California, 92801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.